AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27287858 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient THA
Number of subjects: 220
Study 27287858 — intervention group
Group type: COMPARATOR
Intervention: Inpatient THA
Number of subjects: 220
Study 26590838 — intervention group
Group type: EXPERIMENTAL
Intervention: Web mode
Number of subjects: 170
Study 26590838 — intervention group
Group type: EXPERIMENTAL
Intervention: IVRS mode
Number of subjects: 170
Study 26590838 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper mode
Number of subjects: 170
Study 26590838 — intervention group
Group type: EXPERIMENTAL
Intervention: BFI subscales
Number of subjects: 170
Study 26590838 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mode equivalence
Number of subjects: 170
Study 24383513 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine supplementation
Number of subjects: 21
Study 24383513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 22608580 — intervention group
Group type: EXPERIMENTAL
Intervention: Left nostril group
Number of subjects: 118
Study 22608580 — intervention group
Group type: EXPERIMENTAL
Intervention: Right nostril group
Number of subjects: 118
Study 22608580 — intervention group
Group type: EXPERIMENTAL
Intervention: Both nostril groups (patients with epistaxis)
Number of subjects: 118
Study 22608580 — intervention group
Group type: EXPERIMENTAL
Intervention: Both nostril groups (patients who passed the tube easily)
Number of subjects: 118
Study 20566178 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical treatment based on severity: OSDI (mild) = carboxymethylcelullose, OSDI (moderate) = hidroxypropylmethylcelullose, OSDI (severe) = polyethyleneglycol, OSDI (very severe) = polyethyleneglycol + cyclosporine A 0.05%.
Number of subjects: 144
Study 20566178 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical treatment administered based on severity of symptoms.
Number of subjects: 144
Study 17029771 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh Frozen Plasma (FFP)
Number of subjects: 90
Study 17029771 — intervention group
Group type: COMPARATOR
Intervention: Normal Saline (N/S)
Number of subjects: 90
Study 15333615 — intervention group
Group type: EXPERIMENTAL
Intervention: Model predicting inspiratory flow and area profile based on nasal wall compliance.
Number of subjects: 11
Study 15333615 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic rhinometry and posterior rhinomanometry used to determine initial geometric area and mechanical characteristics.
Number of subjects: 11
Study 12028164 — intervention group
Group type: EXPERIMENTAL
Intervention: tolterodine ER 4 mg once daily (n = 507)
Number of subjects: 1015
Study 12028164 — intervention group
Group type: COMPARATOR
Intervention: placebo (n = 508)
Number of subjects: 1015
Study 10215688 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.4 mg/kg combined with midazolam 0.05 mg/kg
Number of subjects: 30
Study 10215688 — intervention group
Group type: COMPARATOR
Intervention: Pethidine 1.0 mg/kg
Number of subjects: 30
Study 10215688 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine hydrochloride 4.0 mg/kg (oral)
Number of subjects: 30
Study 10215688 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules (oral)
Number of subjects: 30
Study 8570775 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (NTX) at a daily oral dose of 0.5 mg/kg/day
Number of subjects: 0
Study 8570775 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 0
Study 8570775 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (NTX)
Number of subjects: 0
Study 2223424 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg of zopiclone
Number of subjects: 12
Study 2223424 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of carbamazepine
Number of subjects: 12
Study 2223424 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with zopiclone and carbamazepine
Number of subjects: 12
Study 2223424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2223424 — intervention group
Group type: COMPARATOR
Intervention: Clinical test for drunkenness (CTD)
Number of subjects: 12
Study 453259 — intervention group
Group type: EXPERIMENTAL
Intervention: Laminaria placed at the time of the abortifacient injection (Group II, N = 23)
Number of subjects: 80
Study 453259 — intervention group
Group type: EXPERIMENTAL
Intervention: Laminaria placed 4 hours prior to injection (Group III, N = 29)
Number of subjects: 80
Study 453259 — intervention group
Group type: COMPARATOR
Intervention: No additional therapy (Group I, N = 28)
Number of subjects: 80
Study 31838255 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (110 ≤ SBP < 130 mmHg)
Number of subjects: 8511
Study 31838255 — intervention group
Group type: COMPARATOR
Intervention: Mild treatment (130 ≤ SBP < 150 mmHg)
Number of subjects: 8511
Study 31734256 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic liver resection (LLR)
Number of subjects: 21
Study 31734256 — intervention group
Group type: COMPARATOR
Intervention: Open liver resection (OLR)
Number of subjects: 21
Study 28889840 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at CV-12 (Zhongwan) for 30 minutes
Number of subjects: 40
Study 28889840 — intervention group
Group type: COMPARATOR
Intervention: Placebo control at a point on the right side of the abdomen for 30 minutes
Number of subjects: 40
Study 26175420 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiosteoporotic drugs
Number of subjects: 0
Study 26175420 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 23853555 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light exposure at 7,000‐10,000 lux for > 30 minutes for at least 10 days during 2 weeks
Number of subjects: 92
Study 23853555 — intervention group
Group type: COMPARATOR
Intervention: Control group (no bright light exposure, wore sunglasses after work)
Number of subjects: 92
Study 21834326 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive task interdependence
Number of subjects: 66
Study 21834326 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive resource interdependence
Number of subjects: 66
Study 21834326 — intervention group
Group type: COMPARATOR
Intervention: Individualistic learning
Number of subjects: 66
Study 19651564 — intervention group
Group type: EXPERIMENTAL
Intervention: Not on Tobacco (NOT)
Number of subjects: 407
Study 19651564 — intervention group
Group type: COMPARATOR
Intervention: Kickin' Butts
Number of subjects: 407
Study 16881774 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy for bipolar disorder (duration up to 28 months)
Number of subjects: 0
Study 15162892 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins (including fluvastatin)
Number of subjects: 49275
Study 15162892 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 49275
Study 15162892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49275
Study 11260171 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg/kg of zinc sulphate orally
Number of subjects: 104
Study 11260171 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg of zinc sulphate orally
Number of subjects: 104
Study 11260171 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg of zinc sulphate orally
Number of subjects: 104
Study 11260171 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 104
Study 9499663 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytogenetic analysis in a centralized laboratory
Number of subjects: 1115
Study 8427168 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg 3 times daily
Number of subjects: 20
Study 8427168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3687152 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic stimulation (single-frequency pure tone 2 kHz, 120 dB, 5 sec)
Number of subjects: 85
Study 3687152 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic stimulation (sawtooth-modulated pure tone 0.5-2.0 kHz, modulation frequency 10 Hz, 120 dB, 5 sec)
Number of subjects: 85
Study 3687152 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic stimulation (low-frequency sawtooth-modulated pure tone 0.1-0.3 kHz, modulation frequency 10 Hz, 120 dB, 5 sec)
Number of subjects: 85
Study 3687152 — intervention group
Group type: EXPERIMENTAL
Intervention: Light stimulation (electronic photographic flash, luminous intensity 25 x 106 Lux/10-3 sec, 8 flash sequences in 10 sec)
Number of subjects: 85
Study 3687152 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (no acoustic or light-optic signals)
Number of subjects: 85
Study 3687152 — intervention group
Group type: EXPERIMENTAL
Intervention: Genuine light stimulation
Number of subjects: 85
Study 3687152 — intervention group
Group type: COMPARATOR
Intervention: Sham light stimulation
Number of subjects: 85
Study 29921575 — intervention group
Group type: EXPERIMENTAL
Intervention: Shen-Shuai-Ning (SSN) granule, 5 g three times daily for 12 weeks
Number of subjects: 60
Study 29921575 — intervention group
Group type: COMPARATOR
Intervention: Control group (baseline medications and dialysis prescriptions)
Number of subjects: 60
Study 26162647 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (IFX) 5 mg/kg
Number of subjects: 0
Study 26162647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24613110 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human interleukin 11, 1.5 mg subcutaneously
Number of subjects: 40
Study 24613110 — intervention group
Group type: COMPARATOR
Intervention: distilled water (placebo)
Number of subjects: 40
Study 23241457 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid sirolimus-eluting stents with bioresorbable polymers (Orsiro)
Number of subjects: 330
Study 23241457 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting stents with durable polymers (Xience Prime/Xpedition)
Number of subjects: 330
Study 20378829 — intervention group
Group type: EXPERIMENTAL
Intervention: TU-100 2.5 g tid
Number of subjects: 60
Study 20378829 — intervention group
Group type: EXPERIMENTAL
Intervention: TU-100 5 g tid
Number of subjects: 60
Study 20378829 — intervention group
Group type: EXPERIMENTAL
Intervention: TU-100 7.5 g/day
Number of subjects: 60
Study 20378829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 18369202 — intervention group
Group type: EXPERIMENTAL
Intervention: Staging system based on HRCT and PFTs
Number of subjects: 215
Study 18369202 — intervention group
Group type: COMPARATOR
Intervention: HRCT threshold of 20%
Number of subjects: 215
Study 18369202 — intervention group
Group type: COMPARATOR
Intervention: FVC threshold of 70%
Number of subjects: 215
Study 16516788 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspheric profile PRK
Number of subjects: 74
Study 16516788 — intervention group
Group type: COMPARATOR
Intervention: Conventional PRK
Number of subjects: 74
Study 12625641 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill therapy with partial body weight support (BWS)
Number of subjects: 0
Study 12625641 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training
Number of subjects: 0
Study 12625641 — intervention group
Group type: COMPARATOR
Intervention: Locomotor training
Number of subjects: 0
Study 11012471 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyurethane PEG catheter
Number of subjects: 106
Study 11012471 — intervention group
Group type: COMPARATOR
Intervention: Silicone PEG catheter
Number of subjects: 106
Study 8815970 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymizer device
Number of subjects: 14
Study 8815970 — intervention group
Group type: EXPERIMENTAL
Intervention: Transtracheal catheter
Number of subjects: 14
Study 8815970 — intervention group
Group type: COMPARATOR
Intervention: Nasal prongs
Number of subjects: 14
Study 1364955 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclo-cryocoagulation as a single method applied to 12 eyes
Number of subjects: 38
Study 1364955 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cryosurgical method (trans-scleral panretinal cryocoagulation + cyclo-cryocoagulation) applied to 26 eyes
Number of subjects: 38
Study 6697075 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac
Number of subjects: 90
Study 6697075 — intervention group
Group type: EXPERIMENTAL
Intervention: indomethacin
Number of subjects: 90
Study 6697075 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen
Number of subjects: 90
Study 6697075 — intervention group
Group type: EXPERIMENTAL
Intervention: tolfenamic acid
Number of subjects: 90
Study 6697075 — intervention group
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid
Number of subjects: 90
Study 6697075 — intervention group
Group type: EXPERIMENTAL
Intervention: azapropazone
Number of subjects: 90
Study 6697075 — intervention group
Group type: EXPERIMENTAL
Intervention: carprofen
Number of subjects: 90
Study 6697075 — intervention group
Group type: EXPERIMENTAL
Intervention: ibuprofen
Number of subjects: 90
Study 6697075 — intervention group
Group type: COMPARATOR
Intervention: ketoprofen
Number of subjects: 90
Study 6697075 — intervention group
Group type: COMPARATOR
Intervention: proquazone
Number of subjects: 90
Study 30607578 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation (alloHSCT)
Number of subjects: 223
Study 30607578 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 223
Study 30607578 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation (alloHSCT) with negative minimal residual disease after 2 cycles of consolidation
Number of subjects: 223
Study 30258440 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 60
Study 30258440 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 27130049 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5gI/kg
Number of subjects: 57
Study 27130049 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4gI/kg
Number of subjects: 57
Study 27130049 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3gI/kg
Number of subjects: 57
Study 24708604 — intervention group
Group type: EXPERIMENTAL
Intervention: Fundamental movement skill competency (locomotor skills)
Number of subjects: 460
Study 24708604 — intervention group
Group type: EXPERIMENTAL
Intervention: Fundamental movement skill competency (object-control skills)
Number of subjects: 460
Study 22394493 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Group Therapy (CBGT); 12-session protocol
Number of subjects: 165
Study 19636577 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET-CT
Number of subjects: 80
Study 19636577 — intervention group
Group type: COMPARATOR
Intervention: CT alone
Number of subjects: 80
Study 19636577 — intervention group
Group type: COMPARATOR
Intervention: PET
Number of subjects: 80
Study 19636577 — intervention group
Group type: COMPARATOR
Intervention: CT
Number of subjects: 80
Study 19636577 — intervention group
Group type: COMPARATOR
Intervention: PET-CT
Number of subjects: 80
Study 18853113 — intervention group
Group type: EXPERIMENTAL
Intervention: Shugan Jianpi Granule (SJG) 24 g three times a day
Number of subjects: 24
Study 18853113 — intervention group
Group type: EXPERIMENTAL
Intervention: Shugan Jianpi Granule (SJG) 24 g three times a day + Smecta 15 g three times a day
Number of subjects: 24
Study 18853113 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional treatment)
Number of subjects: 24
Study 16447880 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenqi Fuzheng injection (SFI) 100 ml, administered in 5% glucose solution 500 ml for intravenous dripping, once a day for 20 days
Number of subjects: 60
Study 16447880 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerine injection 10 mg, administered in 5% glucose solution 500 ml for intravenous dripping, once a day for 20 days
Number of subjects: 60
Study 12451368 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% tea tree oil shampoo
Number of subjects: 126
Study 12451368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 10360922 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (10 mg/d)
Number of subjects: 0
Study 10360922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7857113 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily application of strong sunscreen
Number of subjects: 53
Study 7857113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 1928879 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol
Number of subjects: 103
Study 1928879 — intervention group
Group type: COMPARATOR
Intervention: Isoetharine
Number of subjects: 103
Study 7049029 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline hydrochloride, 500 mg orally four times daily for 7 days
Number of subjects: 100
Study 7049029 — intervention group
Group type: COMPARATOR
Intervention: Rosaramicin, 250 mg orally four times daily for 7 days
Number of subjects: 100
Study 31257264 — intervention group
Group type: EXPERIMENTAL
Intervention: MFGM 1.0 g + glucosamine 1.5 g
Number of subjects: 53
Study 31257264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 29466164 — intervention group
Group type: EXPERIMENTAL
Intervention: RV3-BB (neonatal schedule)
Number of subjects: 1513
Study 29466164 — intervention group
Group type: EXPERIMENTAL
Intervention: RV3-BB (infant schedule)
Number of subjects: 1513
Study 29466164 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined RV3-BB (neonatal and infant schedule)
Number of subjects: 1513
Study 29466164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1513
Study 26262771 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone 25 mg
Number of subjects: 12
Study 26262771 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone 50 mg
Number of subjects: 12
Study 26262771 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone 100 mg
Number of subjects: 12
Study 26262771 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone (all doses)
Number of subjects: 12
Study 26262771 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone (multiple doses)
Number of subjects: 12
Study 25249056 — intervention group
Group type: EXPERIMENTAL
Intervention: Small Group (SG) treatment (12 members/group)
Number of subjects: 66
Study 25249056 — intervention group
Group type: COMPARATOR
Intervention: Large Group (LG) treatment (30 members/group)
Number of subjects: 66
Study 22499292 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP target <130 mmHg
Number of subjects: 1041
Study 22499292 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP target 130-149 mmHg
Number of subjects: 1041
Study 22499292 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated hypertension at baseline
Number of subjects: 1041
Study 22499292 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanic ethnicity
Number of subjects: 1041
Study 22499292 — intervention group
Group type: EXPERIMENTAL
Intervention: Management at a larger site
Number of subjects: 1041
Study 22499292 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP in target at 6 months
Number of subjects: 1041
Study 22499292 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication adherence
Number of subjects: 1041
Study 22499292 — intervention group
Group type: EXPERIMENTAL
Intervention: Missed appointments
Number of subjects: 1041
Study 20308641 — intervention group
Group type: EXPERIMENTAL
Intervention: CONCERNS + B (bupropion hydrochloride sustained release)
Number of subjects: 349
Study 20308641 — intervention group
Group type: COMPARATOR
Intervention: STANDARD + B (bupropion hydrochloride sustained release)
Number of subjects: 349
Study 20308641 — intervention group
Group type: COMPARATOR
Intervention: STANDARD + P (placebo)
Number of subjects: 349
Study 20308641 — intervention group
Group type: COMPARATOR
Intervention: CONCERNS + P (placebo)
Number of subjects: 349
Study 17579339 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent condom use (100% of acts) for the past 7 days
Number of subjects: 414
Study 17579339 — intervention group
Group type: COMPARATOR
Intervention: No condom use reported
Number of subjects: 414
Study 17579339 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of unprotected acts
Number of subjects: 414
Study 15083634 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril-based blood pressure lowering regimen
Number of subjects: 6105
Study 11457749 — intervention group
Group type: EXPERIMENTAL
Intervention: MMP-2 levels in tissue homogenates and isolated inferior mesenteric SMCs from patients with AAAs
Number of subjects: 34
Study 11457749 — intervention group
Group type: EXPERIMENTAL
Intervention: Histological examination of venous tissue from patients with AAAs
Number of subjects: 34
Study 11457749 — intervention group
Group type: EXPERIMENTAL
Intervention: In situ zymography
Number of subjects: 34
Study 9870006 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual site atrial pacing
Number of subjects: 0
Study 9870006 — intervention group
Group type: EXPERIMENTAL
Intervention: Single site atrial pacing
Number of subjects: 0
Study 9870006 — intervention group
Group type: COMPARATOR
Intervention: Support pacing control (DDI at 50 ppm or VDI)
Number of subjects: 0
Study 8058230 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 100
Study 8058230 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 100
Study 3291371 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 180
Study 3291371 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin plus cyclophosphamide
Number of subjects: 180
Study 3291371 — intervention group
Group type: EXPERIMENTAL
Intervention: Cis-platinum plus 5-fluorouracil plus cyclophosphamide
Number of subjects: 180
Study 31126270 — intervention group
Group type: EXPERIMENTAL
Intervention: 5000 ppm fluoride toothpaste and usual care
Number of subjects: 1200
Study 31126270 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 1200
Study 28569390 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 47
Study 26493429 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led telephone follow ups (Tele-Nursing)
Number of subjects: 60
Study 26493429 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 60
Study 23454666 — intervention group
Group type: EXPERIMENTAL
Intervention: computer-based MetS Program (CBMP)
Number of subjects: 750